CSL shares rated as a buy
Analysts at Goldman Sachs think investors should be buying the dip in the CSL Ltd (ASX: CSL) share price. In response to its half year results, the broker has reaffirmed its buy rating on the biotech giant's shares with a trimmed price target of $318.40. It said: "CSL delivered a mixed result with strong IG growth and +170bps CC Behring Gross Margin (GM%) accretion across 1H25 overshadowed by weakness across its Seqirus influenza vaccines segment. […] Ultimately, CSL Behring (68% of group FY25 Gross Profit) remains the key earnings driver for the group and the result reinforced the earnings drivers for this segment are intact."
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$240.21 |
Change
1.500(0.63%) |
Mkt cap ! $116.3B | |||
| Open | High | Low | Value | Volume |
| $238.71 | $241.05 | $237.37 | $567.1M | 2.283M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1607 | $240.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $240.25 | 394 | 1 |
View Market Depth
| Last trade - 16.10pm 20/06/2025 (20 minute delay) ? |
| CSL (ASX) Chart |